12:00 AM
May 19, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pollinex Quattro Grass: Phase III data

Pollinex Quattro Grass met the primary endpoint of a reduction in the combined symptom/medication score in the Phase III G301 trial to treat grass pollen allergy. Vaccinated patients in the intent-to-treat population had a 13% improvement vs. placebo (p=0.0038). In a prospectively defined population of patients who were fully dose...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >